CHINA PHARMA HOLDINGS, INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $615.21 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was $615.21K, a 2936.14% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was $433.59K, a 5668.84% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-12-31 was -$63.90K.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was $102.60K, a 55.63% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was $94.81K.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was -$204.59K.
- CHINA PHARMA HOLDINGS, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was -$265.80K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month as first filed | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $615.21K 10-Q · filed 2026-08-14 | $1.05M derived: sum of 2 quarters · filed 2026-08-14 | $984.90K derived: sum of 3 quarters · filed 2026-08-14 | $1.09M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $433.59K 10-Q · filed 2026-08-14 | $190.00 10-Q · filed 2026-05-15 | $369.69K derived: sum of 2 quarters · filed 2026-08-14 | $472.29K derived: sum of 3 quarters · filed 2026-08-14 | $492.55K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$63.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $38.70K derived: sum of 2 quarters · filed 2026-04-01 | $58.96K derived: sum of 3 quarters · filed 2026-08-14 | $94.81K 10-K · filed 2026-04-01 | |
| 2025-09-30 | $102.60K 10-Q · filed 2025-11-12 | $122.86K derived: sum of 2 quarters · filed 2026-08-14 | $158.72K 10-Q · filed 2025-11-12 | -$219.03K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $20.26K 10-Q · filed 2026-08-14 | $36.82K 10-Q · filed 2025-08-14 | $56.12K 10-Q · filed 2025-08-14 | -$321.63K derived: sum of 3 quarters · filed 2026-08-14 | -$90.41K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $7.52K 10-Q · filed 2026-08-14 | $19.30K 10-Q · filed 2025-05-14 | -$341.89K derived: sum of 2 quarters · filed 2026-08-14 | -$110.67K derived: sum of 3 quarters · filed 2026-08-14 | -$173.06K derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | -$349.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$118.19K derived: sum of 2 quarters · filed 2026-04-01 | -$180.58K derived: sum of 3 quarters · filed 2026-04-01 | -$204.59K 10-K · filed 2026-04-01 | |
| 2024-09-30 | $231.22K 10-Q · filed 2025-11-12 | $168.83K derived: sum of 2 quarters · filed 2025-11-12 | $144.81K 10-Q · filed 2025-11-12 | $380.31K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$62.39K 10-Q · filed 2025-08-14 | -$86.41K 10-Q · filed 2025-08-14 | $149.09K derived: sum of 3 quarters · filed 2025-08-14 | $256.08K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$24.02K 10-Q · filed 2025-05-14 | $211.48K derived: sum of 2 quarters · filed 2025-05-14 | $318.47K derived: sum of 3 quarters · filed 2025-05-14 | -$516.28K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $235.49K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $342.48K derived: sum of 2 quarters · filed 2025-03-31 | -$492.27K derived: sum of 3 quarters · filed 2025-03-31 | -$265.80K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $106.99K 10-Q · filed 2024-11-13 | -$727.76K derived: sum of 2 quarters · filed 2024-11-13 | -$501.29K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$834.75K 10-Q · filed 2024-08-14 | -$608.28K 10-Q · filed 2024-08-14 | |||
| 2019-09-30 | -$909.89K 10-Q · filed 2019-11-14 | -$1.72M derived: sum of 2 quarters · filed 2019-11-14 | -$885.19K derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2019-06-30 | -$811.16K 10-Q · filed 2019-11-14 | $24.70K derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2019-03-31 | $835.87K 10-Q · filed 2019-11-14 | ||||
| 2018-09-30 | -$1.54M 10-Q · filed 2019-11-14 | -$3.95M derived: sum of 2 quarters · filed 2019-11-14 | -$2.28M derived: sum of 3 quarters · filed 2019-11-14 | ||
| 2018-06-30 | -$2.42M 10-Q · filed 2019-11-14 | -$744.71K derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2018-03-31 | $1.67M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |